Q1 2025 Management View CEO Chris Anzalone announced the closure of a significant licensing and collaboration agreement with Sarepta Therapeutics, which will provide $1.375 billion in upfront and near ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback